Ibogaine by David Dardashti Warns of Kratom's ‘Gateway' Dangers, Citing Alarming Trend in Patient Addiction Cases
The recent FDA actions targeting concentrated 7-OH products—dubbed 'legal morphine' by some researchers—underscore a danger the clinical team at Ibogaine by David Dardashti sees daily. The clinic has witnessed a significant increase in patients arriving with a primary or secondary addiction to kratom, often after being misled by marketing that promotes it as a safe, herbal alternative to opioids. This firsthand clinical data forms the basis for their urgent public warning.
'We are seeing a disturbing pattern,' states David Dardashti. 'Patients come to us after starting with kratom, thinking it's a safe, natural remedy. They don't realize they are developing a true opioid dependency until it's too late. The initial effects fade, tolerance builds, and suddenly they are facing a full-blown addiction with severe withdrawals. The next logical step for many is to seek out something stronger and deadlier, like fentanyl. We are on the front lines of this trend, and it is alarming.'
As referenced in recent reports, experts confirm that while the kratom leaf itself may be mild, concentrated extracts containing 7-OH are significantly more potent and act as pure opioids. This creates the dangerous cycle of dependency that the clinic observes. Users require ever-increasing doses, eventually finding that the legal substance no longer satisfies the addiction it created, driving them toward the illicit drug market.
Despite the alarming trend, the team at Ibogaine by David Dardashti reports significant success in treating kratom addiction and offers a message of hope. Based on extensive clinical experience, the center has found a notable distinction in the recovery process for these patients.
'The good news in this growing crisis is that we've found that individuals dependent on kratom can be brought back to sobriety with less difficulty than those entrenched in long-term Suboxone or fentanyl use,' Dardashti explains. 'Ibogaine therapy works to reset the brain's neurotransmitters and interrupt addiction at the source. For our kratom patients, the process is often smoother and the path to a full recovery is remarkably clear. Our goal is to intervene effectively before the addiction escalates into a far more tragic story.'
About Ibogaine by David Dardashti:
Ibogaine by David Dardashti is a leading treatment center dedicated to helping individuals overcome chemical dependency through a unique combination of ibogaine therapy and holistic care. Founded by David Dardashti, the clinic leverages extensive clinical experience to provide a safe, medically supervised environment for profound psycho-spiritual healing and neurological reset, offering a definitive interruption to the cycle of addiction.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
7 hours ago
- Globe and Mail
CVRx (CVRX) Q2 Revenue Jumps 15%
Key Points Revenue (GAAP) rose 15% to $13.6 million, surpassing both company expectations and analyst estimates. Net loss narrowed on a per-share basis to $(0.57) (GAAP), primarily due to a higher share count despite a slight increase in overall losses. These 10 stocks could mint the next wave of millionaires › CVRx (NASDAQ:CVRX), a medical device innovator focused on heart failure therapy, released its second quarter 2025 earnings on August 4, 2025. The most important news was a Revenue (GAAP) increased to $13.6 million, up 15% year-over-year and above analyst expectations of $13.29 million (GAAP). The company also reported a net loss of $14.7 million, or $(0.57) per share (GAAP). While that loss widened slightly, the per-share figure (GAAP) improved due to an increased share count. The quarter reflected strong commercial progress for its Barostim neuromodulation device despite heavy investment in sales and marketing. Results slightly exceeded internal and external expectations, and management narrowed its revenue guidance to a range of $55.0 million to $57.0 million. Metric Q2 2025 Q2 2025 Estimate Q2 2024 Y/Y Change EPS (GAAP) $(0.57) $(0.52) $(0.65) 12.3% Revenue (GAAP) $13.6 million $13.29 million $11.8 million 15.1% Gross Profit $11.5 million N/A N/A Gross Margin 84% 84% 0% Net Loss $14.7 million $14.0 million -5.0% Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. About CVRx and Its Core Business CVRx (NASDAQ:CVRX) specializes in developing implantable medical devices for treating heart failure. Its leading product, Barostim, is a neuromodulation device—meaning it delivers targeted electrical pulses to nerves in the carotid artery to improve function of the autonomic nervous system. This system regulates key bodily functions, including blood pressure and heart rate. Barostim is designed to treat patients with heart failure with reduced ejection fraction (HFrEF), providing an option that avoids direct implantation in the heart. The company's commercial priorities are building deep adoption in centers with strong heart failure programs and expanding reimbursement pathways to improve access. Solid clinical evidence and reliable regulatory support have been the company's main success factors, along with educating physicians and patients on Barostim's benefits. Quarter Highlights and Key Developments During the period, total revenue (GAAP) reached $13.6 million, outpacing both the company's guides and Wall Street expectations by over 2%. U.S. heart failure revenue remained the largest contributor, climbing to $12.1 million, with units up to 387 from 339 in the prior year. U.S. sales overall were $12.2 million, also up 15% (GAAP). Across the Atlantic, European revenue grew 19% to $1.3 million (GAAP), but the number of European implant units declined from 63 to 61, signaling some softness in procedural volume despite improved pricing or product mix. Active implanting centers in the U.S. grew to 240, reflecting 13 new centers added in the U.S. during the quarter. U.S. sales territories also grew to 47, up from 45, while European territories held steady at five. U.S. revenue accounted for approximately 89.8% of total sales (GAAP), indicating the company's primary growth engine remains domestic. The company attributes revenue gains to both new account additions and greater utilization per center, while the slightly lower European volumes point to variability in adoption across geographies. Gross profit (GAAP) grew 16% from the prior year, maintaining a gross margin of 84%. On the expense side, research and development (R&D) spending declined 11% to $2.5 million, reflecting lower compensation as resources shifted toward commercial growth. Selling, general, and administrative (SG&A) costs (GAAP) increased 11% to $23.4 million, driven mainly by higher employee compensation, travel, and non-cash stock-based grants, with some relief from lower advertising costs. The higher SG&A, while outpaced by revenue growth, resulted in operating and net losses that remain substantial—operating loss (GAAP) at $14.4 million and net loss (GAAP) at $14.7 million. Multiple reimbursement milestones provided stability for Barostim's future. The Centers for Medicare & Medicaid Services (CMS) proposed to retain Barostim as a covered outpatient procedure at the $45,000 payment level, removing some uncertainty for hospitals and ensuring continued access. In addition, CMS proposed favorable physician payment levels of about $550 for new procedure coding effective in 2026. On the clinical front, highlighted real-world data presented at major cardiology conferences showed large reductions in heart failure hospital visits—down 85% for heart failure, 84% for cardiovascular causes, and 86% for all causes—after Barostim implantation, based on comparisons of hospital visits for 306 Barostim patients in the 12 months prior to implant and an average of almost two years post-implant. These real-world results have been well received by physicians and payers, which it views as an important driver of payer support and future uptake. Furthermore, the company is preparing a large pragmatic randomized controlled trial (RCT), potentially enrolling up to 2,000 patients, to further establish Barostim's efficacy, as discussed in recent management commentary. Although the timing and costs of that effort depend on regulatory approval and payer support, management sees it as a long-term enabler of broader use. The company finished the quarter with $95.0 million in cash and cash equivalents, down from $105.9 million at year end 2024. Net cash used for operations and investing was $8.0 million, showing some improvement from $10.2 million a year ago, but still indicating ongoing cash burn. Long-term debt remained steady at $49.4 million. Looking Ahead: Guidance and Watch Items For fiscal 2025, management narrowed its revenue guidance to $55.0–$57.0 million, tightening the prior range and signaling increased confidence from better visibility into commercial results. The company expects gross margin to remain high at 83–84%. Operating expenses are now projected at $96.0–$98.0 million, a slight increase at the midpoint, reflecting ongoing investments in sales and account growth. Revenue is expected in the range of $13.7–$14.7 million for the next quarter, suggesting continued double-digit revenue growth ahead, as evidenced by a 15% year-over-year increase. Areas to watch in the coming quarters include progress in adding new implanting centers, the effectiveness and productivity of the enlarged sales force, and movement toward scaling revenues faster than expenses. Investors will also monitor any shift in European procedure volumes, cash usage trends, and the company's progress on the planned large RCT, as this trial could both validate Barostim's utility and expand the addressable market if successful. CVRX does not currently pay a dividend. Revenue and net income presented using U.S. generally accepted accounting principles (GAAP) unless otherwise noted. Where to invest $1,000 right now When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor's total average return is 1,019%* — a market-crushing outperformance compared to 178% for the S&P 500. They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor. See the stocks » *Stock Advisor returns as of August 4, 2025
Globe and Mail
12 hours ago
- Globe and Mail
EULA Home Care Agency Reaffirms Commitment to Provide Senior Home Care in Harrisburg
Smiling together, a caregiver and senior share a warm moment over a medication check—capturing the heart of EULA Home Care Agency Reaffirms Commitment to Provide Senior Home Care in Harrisburg. This image reflects the trust, compassion, and personalized support EULA delivers to every family they serve in the Harrisburg community. EULA Home Care Agency reaffirms its commitment to senior care in Harrisburg, NC, ensuring aging residents have access to compassionate, personalized in-home support. The agency's professional caregivers assist with daily tasks, mobility, and companionship, helping seniors live independently while giving families peace of mind. With a growing senior population, EULA continues to be a trusted resource for reliable, dignified care rooted in community values. Harrisburg, NC - EULA Home Care Agency, a trusted provider of in-home senior care services, today announced its continued and unwavering commitment to the families and elderly residents of Harrisburg, NC. The agency reaffirms its mission to deliver high-quality, compassionate care, enabling seniors to live comfortably and independently in their own homes. This reaffirmation comes at a crucial time when accessible and reliable care is more important than ever for the community. One of the primary benefits of the services offered by EULA Home Care Agency is the creation of personalized care plans tailored to each individual's unique needs and requirements. Recognizing that every senior has different requirements, the agency's professional caregivers provide support ranging from assistance with daily living activities, such as bathing and meal preparation, to medication reminders and mobility support. This customized approach to senior care in Harrisburg, NC, not only ensures the physical safety and well-being of clients but also promotes a greater sense of independence and dignity. Furthermore, the agency provides invaluable peace of mind for families. Entrusting the care of a loved one to a professional can be a difficult decision, but EULA Home Care Agency alleviates this stress by offering reliable, vetted, and compassionate caregivers. Families can rest assured that their senior relatives are receiving exceptional Harrisburg senior home care, allowing family caregivers to get much-needed respite, reduce burnout, and spend more quality time with their loved ones without the constant pressure of caregiving responsibilities. "Our mission has always been deeply rooted in the community we serve," said Davetta Williams, founder of EULA Home Care Agency. "We believe every senior deserves to age with dignity and grace in the comfort of their own home. We are here to ensure that families in Harrisburg know they have a reliable partner to turn to for compassionate and skilled care, making the aging process a smoother and more positive experience for everyone involved." As the senior population in the region continues to grow, the need for dependable in-home care services has become increasingly evident. EULA Home Care Agency addresses this demand by focusing on a holistic approach that supports not only the physical health of seniors but also their emotional and social well-being. By providing companionship and fostering genuine connections, their caregivers help combat the loneliness and isolation that many seniors can experience. EULA Home Care Agency remains dedicated to being a pillar of support for the Harrisburg community. By continuing to offer accessible and professional services, the agency ensures that local families have a trusted resource for senior care. Families seeking more information about the services provided are encouraged to visit the agency's website or call their office directly to schedule a complimentary consultation. For more information about EULA Home Care Agency and their senior home care in Harrisburg, NC, please visit their website at About EULA Home Care Agency: EULA Home Care Agency is a premier provider of non-medical, in-home care services for seniors in Harrisburg, NC, and the surrounding areas. Founded by Davetta Williams, the agency is dedicated to delivering compassionate, professional, and personalized care that enables seniors to live safely and comfortably in their own homes. Media Contact Company Name: EULA Home Care Agency Contact Person: Davetta Williams Email: Send Email Phone: +1 704 549 8300 Address: 8430 University Executive Park Dr Suite 606 City: Charlotte State: NC Country: United States Website:
Globe and Mail
12 hours ago
- Globe and Mail
Nest and Care Continues Offering Families Comprehensive Long-Term Care Assistance in Bethesda, MD
A compassionate caregiver helps an elderly man transition safely from his wheelchair near a sunlit bedroom, symbolizing trust, dignity, and professional support. This image reflects the heart of Nest and Care Continues Offering Families Comprehensive Long-Term Care Assistance in Bethesda, MD, where personalized care ensures seniors thrive comfortably at home while families gain peace of mind. Nest and Care reaffirms its commitment to delivering compassionate long-term care assistance in Bethesda, MD. With personalized care plans and highly trained caregivers, the agency supports seniors in maintaining independence and dignity at home. Families benefit from peace of mind, knowing their loved ones are safe and well-cared for. Nest and Care continues to be a trusted partner, offering professional support that enhances both client well-being and family life. Bethesda, MD - Nest and Care today announced its continued commitment to serving the community by providing expert long-term care assistance in Bethesda. The organization, led by Kat Villanueva, reaffirms its mission to support families by offering dependable, personalized, and compassionate care solutions for their aging loved ones, ensuring they can thrive in a safe and comfortable environment. One of the primary benefits of the services provided by Nest and Care is the focus on customized care plans that promote independence and enhance quality of life. Each plan is meticulously developed to meet the unique physical, emotional, and social needs of the individual. This tailored approach ensures that clients receive the precise level of support they require, from assistance with daily activities and medication management to companionship, all delivered by highly trained and empathetic caregivers. This fosters a sense of dignity and well-being for the client. Furthermore, Nest and Care provide invaluable support to the families of those receiving care. By entrusting the responsibilities of daily care to professionals, family members are relieved of significant stress and are free to spend more meaningful, quality time with their loved ones. This service offers families critical reassurance, knowing that their relatives are in safe, capable hands. This peace of mind is central to the agency's mission to support the entire family unit through their Bethesda long-term care services. 'Our goal has always been to be more than just a care provider; we strive to become a trusted extension of the family,' said Kat Villanueva, founder of Nest and Care. 'Seeing the relief and peace of mind on a family's face when they know their loved one is safe, happy, and receiving the best possible care is why we do what we do. We are proud to continue this important work in the Bethesda community.' Nest and Care is a premier provider of long-term care services dedicated to helping seniors live gracefully and comfortably. The agency is known for its rigorous caregiver screening process and its commitment to continuous training, ensuring the highest standards of care. Their philosophy is rooted in compassion, respect, and a deep understanding of the challenges families face when seeking care solutions. For more information about Nest and Care and their long-term care assistance in Bethesda, MD, please visit their website at About Nest and Care Home Health Care: Nest and Care is an agency dedicated to helping seniors live with dignity, comfort, and independence. Founded on the principles of compassion, respect, and reliability, the company specializes in creating customized care plans tailored to the unique needs of each individual and their family. Nest and Care's team of highly trained and carefully vetted caregivers provides a comprehensive range of non-medical services, from assistance with daily living and personal care to meaningful companionship. The agency is committed to being a trusted community partner, ensuring that families in the Bethesda area have a reliable and caring resource to enhance their loved ones' quality of life and provide essential peace of mind. Media Contact Company Name: Nest And Care Contact Person: Kat Villanueva Email: Send Email Phone: +1 213 448 9798 Address: 10411 Motor City Dr Suite 325 City: Bethesda State: Maryland 20817 Country: United States Website:
